Weiss Ratings Reiterates "Sell (D-)" Rating for Celularity (NASDAQ:CELU)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for Celularity (NASDAQ:CELU), reflecting a negative outlook from the ratings agency.
• The company's stock is currently trading around $2.15, with a 52-week low of $1.00 and a high of $5.22.
• Despite the negative ratings, some analysts have a hopeful outlook, with a "Buy" rating from one analyst and a price target of $6.00 from others.

Celularity (NASDAQ:CELU - Get Free Report)'s stock had its "sell (d-)" rating restated by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also recently issued reports on the company. Wall Street Zen cut Celularity from a "hold" rating to a "sell" rating in a report on Friday, September 5th. WBB Securities raised Celularity from a "hold" rating to a "buy" rating and set a $6.00 price objective for the company in a report on Tuesday, September 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $6.00.

Celularity Price Performance

Shares of Celularity stock traded up $0.11 on Wednesday, reaching $2.15. 182,569 shares of the company's stock were exchanged, compared to its average volume of 169,325. Celularity has a 52 week low of $1.00 and a 52 week high of $5.22. The firm's 50-day moving average is $2.84 and its two-hundred day moving average is $2.28.

Celularity (NASDAQ:CELU - Get Free Report) last posted its quarterly earnings results on Friday, August 29th. The company reported ($1.02) earnings per share (EPS) for the quarter. The business had revenue of $5.74 million for the quarter. Celularity had a negative return on equity of 459.57% and a negative net margin of 165.22%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd boosted its stake in Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock worth $42,000 after buying an additional 11,057 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Celularity in the first quarter worth approximately $34,000. Bank of America Corp DE boosted its stake in Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock worth $73,000 after buying an additional 35,023 shares in the last quarter. Two Sigma Investments LP purchased a new stake in Celularity in the fourth quarter worth approximately $93,000. Finally, Valmark Advisers Inc. purchased a new stake in Celularity in the second quarter worth approximately $98,000. Hedge funds and other institutional investors own 19.02% of the company's stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.